Organigram (OGI) Price Target Increased to C$7.00 by Analysts at Eight Capital

Organigram (CVE:OGI) had its target price lifted by analysts at Eight Capital from C$4.50 to C$7.00 in a research report issued on Monday. Eight Capital’s price objective would suggest a potential upside of 62.04% from the stock’s previous close.

Separately, Canaccord Genuity set a C$5.50 price target on Organigram in a research note on Wednesday, March 7th.

Organigram (CVE OGI) traded up C$0.01 during trading on Monday, hitting C$4.32. The company had a trading volume of 331,866 shares, compared to its average volume of 2,237,194. Organigram has a 12-month low of C$2.00 and a 12-month high of C$5.68. The stock has a market capitalization of $526.95, a P/E ratio of -39.27 and a beta of 8.35.

Organigram (CVE:OGI) last posted its quarterly earnings results on Monday, January 29th. The company reported C($0.01) earnings per share for the quarter, meeting the Zacks’ consensus estimate of C($0.01). The business had revenue of C$2.69 million during the quarter, compared to analysts’ expectations of C$2.86 million.

ILLEGAL ACTIVITY NOTICE: “Organigram (OGI) Price Target Increased to C$7.00 by Analysts at Eight Capital” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at

Organigram Company Profile

OrganiGram Holdings Inc, through its subsidiary, Organigram Inc, produces and sells medical marijuana in Canada. The company was founded in 2013 and is based in Moncton, Canada.

Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with's FREE daily email newsletter.

Leave a Reply